WuXi STA, a global leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to share that it has been named a recipient of the 2023 CDMO Leadership Award for the ninth consecutive year. WuXi STA received recognition in two core categories: Capabilities and Reliabilities, which underscores the company’s ongoing commitment to supporting its global partners in new drug development.
For the 2023 CDMO Leadership Awards, Outsourced Pharma and Life Science Leader Magazine teamed up with Industry Standard Research (ISR) to conduct the Contract Manufacturing Quality Benchmarking survey that captured input from decision makers, aiming to recognize the top CDMOs achieving outstanding performance. 72 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey, covering all sizes of companies from both Pharma and Biopharma industries.
With over two decades of dedication to the CDMO industry, WuXi STA has established a global R&D and manufacturing network of 14 sites across North America, Asia, and Europe with over 14,000 employees, serving more than 1,200 customers in 2022 alone. By leveraging its end-to-end integrated CRDMO platform and a global standard quality system, WuXi STA has supported the approval of 38 new drugs since 2017. The products manufactured by the company have been launched in 105 countries, helping millions of patients worldwide.
Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, commented, “We are honored to receive the 2023 CDMO Leadership Award again this year, and we are grateful to our partners for their recognition and trust. WuXi STA remains committed to delivering world-class CRDMO services to accelerate life-changing medicines to market for the benefit of patients around the world.”
About WuXi STA
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations across Asia, North America, and Europe. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate. For more information, please visit: https://sta.wuxiapptec.com/
